Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
European Urology
|
May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
European Urology
|
June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2020
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A Palma, Robert Olson, Stephen Harrow, et al.
Cancer
|
May 24, 2023
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol
Biniam Kidane, Ian J Gerard, Jonathan Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A Rosenthal, Chen Hu, Oliver Sartor, et al.
Lancet (London, England)
|
May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Alan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
JAMA Oncology
|
March 7, 2024
Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial
David A Palma, Houda Bahig, Andrew Hope, et al.
BMC Cancer
|
August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 5, 2025
Dosimetric Outcomes of SBRT to Ultra-central Lung Tumors: Lessons from the SUNSET trial
Rohan Salunkhe, David A Palma, Andrew Warner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 29, 2020
Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement
Matthias Guckenberger, Claus Belka, Andrea Bezjak, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
European Urology
|
May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
European Urology
|
June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2020
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A Palma, Robert Olson, Stephen Harrow, et al.
Cancer
|
May 24, 2023
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol
Biniam Kidane, Ian J Gerard, Jonathan Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A Rosenthal, Chen Hu, Oliver Sartor, et al.
Lancet (London, England)
|
May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Alan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
JAMA Oncology
|
March 7, 2024
Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial
David A Palma, Houda Bahig, Andrew Hope, et al.
BMC Cancer
|
August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 5, 2025
Dosimetric Outcomes of SBRT to Ultra-central Lung Tumors: Lessons from the SUNSET trial
Rohan Salunkhe, David A Palma, Andrew Warner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 29, 2020
Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement
Matthias Guckenberger, Claus Belka, Andrea Bezjak, et al.
Page
of 9